公开(公告)号：WO2004082822A3

公开(公告)日：2005-07-07

申请号：PCT/US2004007896

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC ,  IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

Inventor： IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

IPC: A61K31/7072 ,  B01J20060101 ,  C07D251/10 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12

CPC classification number: C07H1/06 ,  C07H19/12

Abstract: The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.

Abstract translation: 本发明包括用于分离基本上不含其它形式的5-氮杂胞苷的结晶形式I的方法，其中5-氮杂胞苷由下式表示：本发明还包括包含5-氮杂胞苷的形式I的药物组合物。

公开(公告)号：WO2004082619A3

公开(公告)日：2005-05-26

申请号：PCT/US2004007895

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC ,  IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

Inventor： IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

IPC: A61K20060101 ,  A61K31/4436 ,  A61K31/53 ,  A61K31/7072 ,  C07D411/04 ,  C07H19/048 ,  C07H19/12

CPC classification number: A61K31/7068 ,  A61K31/706 ,  C07H19/048 ,  C07H19/12

Abstract: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacythidine is represented by the formula (I). The invention also includes pharmaceutical compositions comprising said forms.

Abstract translation: 本发明提供5-氮杂胞苷的新型多晶型和假多晶型结晶形式，以及制备所述形式的方法，其中5-氮杂环丁烷由式（I）表示。 本发明还包括包含所述形式的药物组合物。

公开(公告)号：EP1608634A4

公开(公告)日：2006-03-15

申请号：EP04721078

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC

Inventor： IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

IPC: C07D251/10 ,  A61K31/7072 ,  B01J20060101 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12

CPC classification number: C07H1/06 ,  C07H19/12

Abstract: The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.

公开(公告)号：EP1610784A4

公开(公告)日：2007-11-07

申请号：EP04721074

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC

Inventor： IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

IPC: C07H19/12 ,  A61K20060101 ,  A61K31/4436 ,  A61K31/53 ,  A61K31/7072 ,  C07D411/04 ,  C07H19/048

CPC classification number: A61K31/7068 ,  A61K31/706 ,  C07H19/048 ,  C07H19/12

Abstract: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula (I). The invention also includes pharmaceutical compositions comprising said forms.

公开(公告)号：CA2518973A1

公开(公告)日：2004-09-30

申请号：CA2518973

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC

Inventor： SILVEY GARY L ,  BLUMBERGS PETER ,  IONESCU DUMITRU

IPC: A61K31/7072 ,  B01J20060101 ,  C07D251/10 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12

Abstract: The invention includes methods for isolating crystalline Form I of 5- azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.

公开(公告)号：BRPI0408506A

公开(公告)日：2006-03-14

申请号：BRPI0408506

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC

Inventor： IONESCU DUMITRU ,  BLUMBERGS PETER ,  SILVEY GARY L

IPC: A61K31/7072 ,  B01J20060101 ,  C07D251/10 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12

公开(公告)号：AU2004222274A1

公开(公告)日：2004-09-30

申请号：AU2004222274

申请日：2004-03-16

Applicant: PHARMION CORP ,  ASH STEVENS INC

Inventor： BLUMBERGS PETER ,  SILVEY GARY L ,  IONESCU DUMITRU

IPC: A61K31/7072 ,  B01J20060101 ,  C07D251/10 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12

公开(公告)号：MXPA05009969A

公开(公告)日：2006-02-17

申请号：MXPA05009969

申请日：2004-03-16

Applicant: PHARMION CORP

Inventor： BLUMBERGS PETER

IPC: B01J20060101 ,  A61K31/7072 ,  C07D251/10 ,  C07D253/02 ,  C07D405/04 ,  C07H19/12 ,  B01J00/00

Abstract: La invencion incluye metodo para aislar la Forma cristalina I de la 5-azacitidina sustancialmente libre de otras formas, en donde la 5-azacitidina esta representada por la formula: (ver formula). La invencion tambien incluye composiciones farmaceuticas que comprenden la Forma I de la 5-azacitidina.